What it's for (Indications)
- Erythromycin is a macrolide antibiotic prescribed for the treatment of various bacterial infections susceptible to its action.
- Primary indications include respiratory tract infections such as pharyngitis, tonsillitis, sinusitis, bronchitis, and community-acquired pneumonia caused by organisms like *Streptococcus pneumoniae*, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Legionella pneumophila*.
- It is also effective against certain skin and soft tissue infections, including impetigo and erythrasma.
- Furthermore, erythromycin is utilized in treating pertussis (whooping cough), diphtheria (as an adjunct to antitoxin), *Chlamydia trachomatis* infections affecting the genitourinary tract (e.
- g.
- , cervicitis, urethritis) and conjunctiva (e.
- g.
- , neonatal conjunctivitis), and early syphilis in penicillin-allergic patients.
- It can serve as an alternative for prophylaxis of rheumatic fever in individuals sensitive to penicillin.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of erythromycin varies significantly depending on the specific salt form (e.g., ethylsuccinate, stearate, base), the severity and type of infection, and patient factors such as age and weight. For the oral suspension (e.g., Erythrocin 200mg/5ml, typically erythromycin ethylsuccinate), the recommended adult dose is commonly 400 mg every 6 hours or 800 mg every 12 hours, with a maximum daily dose often not exceeding 4 grams. For pediatric patients, the usual dosage is 30 to 50 mg/kg/day, administered in equally divided doses every 6 to 12 hours. In severe infections, this dose may be increased up to 100 mg/kg/day, also in divided doses. Treatment duration typically ranges from 7 to 14 days, though for streptococcal pharyngitis, a full 10-day course is crucial to prevent rheumatic fever. It is important to note that dosing adjustments may be necessary in patients with severe renal or hepatic impairment. |
Safety & Warnings
Common Side Effects
- Erythromycin therapy is commonly associated with gastrointestinal disturbances, which are among the most frequent adverse events, including abdominal pain, cramping, nausea, vomiting, and diarrhea.
- These effects are often dose-related and more pronounced with certain salt forms.
- Less common side effects may include skin rashes, urticaria, and other allergic reactions, ranging from mild to severe (e.
- g.
- , anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis).
- Cardiac adverse events, although rare, are serious and include QT prolongation and Torsades de Pointes, particularly in patients with pre-existing cardiac conditions, electrolyte imbalances, or concomitant use of other QT-prolonging drugs.
- Hepatotoxicity, characterized by cholestatic hepatitis, can occur, especially with the estolate form, and necessitates monitoring of liver function.
- Reversible hearing loss or ototoxicity has been reported, typically at high doses or in patients with renal insufficiency.
- *Clostridium difficile*-associated diarrhea (CDAD) is also a potential complication, ranging from mild to life-threatening colitis.
Serious Warnings
- Black Box Warning: Erythromycin does not carry a formal FDA Black Box Warning. However, it is associated with several serious risks that warrant careful consideration and monitoring, functioning effectively as 'Serious Warnings' due to their clinical significance. These include the potential for significant QT prolongation and the induction of Torsades de Pointes, a life-threatening ventricular arrhythmia. This risk is amplified when erythromycin is co-administered with other QT-prolonging drugs or in patients with pre-existing cardiac conditions, electrolyte imbalances (hypokalemia, hypomagnesemia), or significant bradycardia. Furthermore, erythromycin is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme system, leading to potentially dangerous increases in the plasma concentrations of many co-administered medications that are CYP3A4 substrates. Such interactions can result in severe adverse events, including rhabdomyolysis (with statins), profound hypotension (with certain calcium channel blockers), and acute ergotism (with ergot alkaloids). There is also a documented risk of infantile hypertrophic pyloric stenosis (IHPS) in neonates exposed to erythromycin. Clinicians must meticulously assess patient history, concomitant medications, and monitor for adverse effects to mitigate these serious risks.
- Erythromycin must be used with caution in patients with hepatic dysfunction due to the risk of cholestatic hepatitis, which can manifest as jaundice, fever, nausea, and abdominal pain.
- Liver function tests should be monitored in these individuals.
- The drug is associated with prolongation of the QT interval on the electrocardiogram, potentially leading to ventricular arrhythmias, including Torsades de Pointes.
- This risk is elevated in patients with congenital long QT syndrome, uncorrected hypokalemia or hypomagnesemia, significant bradycardia, or those concurrently receiving other medications known to prolong the QT interval (e.
- g.
- , antiarrhythmics, antipsychotics).
- There is a documented risk of infantile hypertrophic pyloric stenosis (IHPS) in neonates, particularly those less than one month of age, treated with erythromycin, especially for pertussis prophylaxis.
- Close monitoring for symptoms such as vomiting and irritability is essential.
- *Clostridium difficile*-associated diarrhea (CDAD), ranging from mild diarrhea to fatal colitis, has been reported with nearly all antibacterial agents, including erythromycin, and should be considered in any patient presenting with diarrhea following antibiotic use.
How it Works (Mechanism of Action)
Erythromycin exerts its antibacterial effect by inhibiting bacterial protein synthesis. As a macrolide antibiotic, it specifically binds reversibly to the 50S ribosomal subunit of susceptible microorganisms. This binding action prevents the translocation of peptidyl tRNA from the acceptor (A) site to the peptidyl (P) site of the ribosome, thereby blocking the elongation of polypeptide chains and inhibiting the synthesis of bacterial proteins. This mechanism effectively halts bacterial growth and replication. Depending on the concentration of the drug at the site of infection and the susceptibility of the target organism, erythromycin can be bacteriostatic (inhibiting growth) or bactericidal (killing bacteria). Its spectrum of activity primarily covers Gram-positive bacteria, some Gram-negative organisms, and atypical bacteria like *Mycoplasma*, *Legionella*, and *Chlamydia*.